dendritic cell vaccine with MHC-I peptides

A **dendritic cell vaccine with MHC-I peptides** is a cell-based immunotherapeutic product created by loading dendritic cells (DCs) ex vivo with peptides specifically designed to bind to **major histocompatibility complex class I (MHC-I)** molecules. These peptides are usually derived from tumor-specific or tumor-associated antigens, processed and presented on the cell surface by DCs. Upon administration, the vaccine aims to initiate and amplify antigen-specific **CD8+ cytotoxic T lymphocyte** responses against cancer cells. This approach leverages the potent antigen-presenting capabilities of DCs and the specificity of MHC-I restricted peptide antigens to trigger targeted immune destruction of tumor cells. DC vaccines with MHC-I peptide loading are typically **personalized** and may incorporate multiple epitopes, often chosen using immunoproteomic or motif prediction methods to maximize tumor coverage and immune activation. Common indications include advanced or recurrent cancers such as melanoma, pancreatic cancer, and others in various investigational or early clinical trial settings. Mechanistically, the vaccine facilitates antigen cross-presentation by DCs and activation of cytotoxic T lymphocytes specific to the chosen tumor neoantigens[1][3][5].

Brand names

dendritic cell vaccine with MHC-I peptides

Other names

DC vaccine with MHC-I peptidespeptide-pulsed dendritic cell vaccine